# Liquid Embolic Market

> Liquid Embolic Market Research Report By Therapeutic Modality (N-Butyl Cyanoacrylate (NBCA), Ethylene Vinyl Alcohol Copolymer (Onyx), Polyvinyl Alcohol (PVA)), By Application (Arteriovenous Malformations (AVMs), Dural Arteriovenous Fistulas (DAVFs), Carotid Cavernous Fistulas (CCFs)), By End User (Hospitals, Ambulatory Surgical Centers (ASCs), .Neurointerventional Centers) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.68%
- **2024:** $ 8.69 Billion
- **2025:** $ 9.36 Billion
- **2035:** $ 19.61 Billion
- **Key Players:** Companies such as Medtronic(US), Johnson & Johnson (US), Stryker (US), Terumo Corporation (JP), Penumbra, Inc. (US), B. Braun Melsungen AG (DE), Boston Scientific Corporation (US), Cook Medical (US), Asahi Intecc Co., Ltd. (JP) are some of the major participants in the global market.

**Report ID:** MRFR/HC/39102-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/liquid-embolic-market-41151

---

## Market Summary

## **Liquid Embolic Market Overview**

As per MRFR analysis, the Liquid Embolic Market Size was estimated at 7.49 (USD Billion) in 2022. The Liquid Embolic Market Industry is expected to grow from 8.07(USD Billion) in 2023 to 15.7 (USD Billion) by 2032. The Liquid Embolic Market CAGR (growth rate) is expected to be around 7.68% during the forecast period (2024 - 2032).

### **Key Liquid Embolic Market Trends Highlighted**

The Liquid Embolic market is evolving due to new technologies and increasing use cases in many areas of medicine. One of the trends that can be mentioned is the growing use of neurovascular embolization for patients with cerebral aneurysms and arteriovenous malformations (AVMs). This growth is because of the effectiveness and minimally invasive nature of these procedures.

Moreover, the availability of newer embolic agents that have improved biocompatibility, targeting, and release properties creates prospects for market growth. Also, the rising incidences of vascular diseases such as peripheral artery disease and uterine fibroids are forcing the push for liquid embolic to be used rather than liquid embolic rather than other surgery methods.

The other trend nowadays is the introduction of precision embolization, the ability to deliver an embolic agent to an exact point in a specific body part during a procedure. This allows for better results to be achieved with fewer risks. In general, the Liquid Embolic market is expected to grow further as more innovations in medical devices and treatment approaches can provide better ways to manage different diseases.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Liquid Embolic Market Drivers**

### Rising Prevalence of Vascular Malformations and Neurological Disorders

The rising prevalence of vascular malformations and neurological disorders is a major driver of growth in the Liquid Embolic Market Industry. Vascular malformations are abnormal connections between blood vessels that can occur anywhere in the body, while neurological disorders are conditions that affect the nervous system. Both of these conditions can cause a variety of symptoms, including pain, swelling, and neurological deficits.

Liquid embolic agents are used to treat these conditions by blocking off the affected blood vessels or by providing a scaffold for the formation of new blood vessels.This growth will be driven by the rising prevalence of vascular malformations and neurological disorders, as well as the increasing awareness of liquid embolic agents and their benefits.

### Technological Advancements

Another key driver of growth in the Liquid Embolic Market Industry is technological advances. Over the past few years, there have been multiple significant achievements in the development of liquid embolic agents. The application of technological advancements has led to the creation of agents that are more efficacious, less invasive, and easier to use. One of the most significant technological advancements in the development of LEB agents is microspheres. These are small, round particles made from a variety of different materials, including polymers, metals, and ceramics.

They can be injected into the bloodstream and then guided to specific locations of the body. When in place, microspheres can block off blood vessels or serve as a scaffold for the construction of new blood vessels. Despite being highly efficacious in blocking off vessels, microspheres are less invasive and easier to use and, therefore, are rapidly gaining popularity in the treatment of vascular malformations and different neurological issues.

### Growing Demand for Minimally Invasive Procedures

The growing demand for minimally invasive procedures is also contributing to the growth of the Liquid Embolic Market Industry. Minimally invasive procedures are surgical procedures that are performed through small incisions. These procedures are less invasive than traditional open surgery, and they offer a number of benefits, including reduced pain, scarring, and recovery time. Liquid embolic agents can be used in a variety of minimally invasive procedures. For example, liquid embolic agents can be used to treat vascular malformations and neurological disorders. In these procedures, liquid embolic agents are injected into the affected blood vessels or the surrounding tissue.

The liquid embolic agents then block off the blood vessels or provide a scaffold for the formation of new blood vessels. The growing demand for minimally invasive procedures is expected to continue to drive the growth of the Liquid Embolic Market Industry in the coming years.

## **Liquid Embolic Market Segment Insights**

### **Liquid Embolic Market Therapeutic Modality Insights  **

N-butyl cyanoacrylate (NBCA), Ethylene Vinyl Alcohol Copolymer (Onyx), and Polyvinyl Alcohol (PVA) are the three primary therapeutic modalities employed in liquid embolic procedures. NBCA is a fast-acting liquid embolic agent widely used for the treatment of hypervascularized tumors and arteriovenous malformations due to its rapid polymerization upon contact with ionic solutions. It offers precise embolization and minimal tissue damage, making it suitable for embolizing small and medium-sized vessels.

Onyx, a copolymer of ethylene and vinyl alcohol, is a non-adhesive liquid embolic agent known for its ability to penetrate deeply into vascular structures.Its high viscosity allows for controlled deployment and conformability, making it ideal for embolizing larger vessels and irregular vascular networks. Onyx is commonly used in the embolization of cerebral aneurysms, dural arteriovenous fistulas, and spinal vascular malformations. PVA is a water-soluble liquid embolic agent with excellent biocompatibility and minimal inflammatory response. It is often used in combination with other embolic agents to achieve a more complete and durable embolization.

PVA is particularly useful for embolizing larger vessels and cavities, such as uterine fibroids, varicoceles, and arteriovenous malformations.These three therapeutic modalities collectively represent a significant portion of the Liquid Embolic Market revenue. The market for NBCA is projected to grow at a steady pace, driven by its widespread adoption in neurovascular and peripheral embolizations. Onyx is expected to witness a robust growth rate due to its increasing use in complex neurovascular procedures. PVA is anticipated to gain popularity in the embolization of larger vessels and cavities, contributing to the overall growth of the therapeutic modality segment.

Understanding the specific characteristics, applications, and growth potential of each therapeutic modality is crucial for manufacturers and healthcare providers to make informed decisions regarding product development, treatment strategies, and market positioning.By leveraging this data, stakeholders can effectively address the evolving needs of patients and capitalize on the opportunities presented by the Liquid Embolic Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Liquid Embolic Market Application Insights  **

Arteriovenous malformations, dural arteriovenous fistulas, and carotid cavernous fistulas are all conditions that can be treated with liquid embolic agents. Arteriovenous malformations are abnormal connections between arteries and veins, dural arteriovenous fistulas are abnormal connections between arteries and veins in the dura mater, and carotid cavernous fistulas are abnormal connections between the carotid artery and the cavernous sinus. This is due to the rising incidence of these conditions, as well as the increasing use of liquid embolic agents in treatment.Arteriovenous malformations are the most common type of cerebrovascular malformation, accounting for approximately 50% of all cases.

Dural arteriovenous fistulas are a rare type of literature review cerebrovascular malformation, accounting for approximately 10% of all cases. Carotid cavernous fistulas are the least common type, accounting for around 5% of all cases. The treatment for all three conditions usually involves either surgery, embolization, or both. Surgical or embolic procedures are increasingly being used for their embolization, as they can occlude the blood vessels and stop the bleeding.The Liquid Embolic Market for these conditions is very competitive, with many of the major players being involved in the market.

Some of the major players in the industry are Boston Scientific Corporation, Johnson & Johnson, and Medtronic plc.

### **Liquid Embolic Market End User Insights  **

The Liquid Embolic Market Segmentation by End User into Hospitals, Ambulatory Surgical Centers (ASCs), and Neurointerventional Centers offers valuable insights into the industry dynamics. Hospitals dominate the market, accounting for a significant share of the Liquid Embolic Market revenue due to the high volume of embolization procedures performed in these settings. Ambulatory Surgical Centers (ASCs) are gaining traction as they provide cost-effective and convenient options for patients.

Neurointerventional centers specializing in minimally invasive treatments for neurological disorders are expected to witness steady growth driven by the rising prevalence of conditions like stroke and brain tumors.These segments collectively contribute to the overall growth of the Liquid Embolic Market, influenced by factors such as technological advancements, increasing patient awareness, and expanding healthcare infrastructure.

### **Liquid Embolic Market Regional Insights  **

The Liquid Embolic Market is segmented into North America, Europe, APAC, South America, and MEA. North America is the largest market for liquid embolic agents, followed by Europe. The growth of the North American market is attributed to the increasing prevalence of vascular diseases, the rising demand for minimally invasive procedures, and the growing adoption of advanced embolic agents.

The European market is also growing steadily, driven by the increasing awareness of liquid embolic agents and the growing number of endovascular procedures.The APAC market is expected to witness significant growth in the coming years, owing to the rising incidence of vascular diseases and the growing healthcare expenditure in the region. The South American and MEA markets are also expected to grow at a healthy pace, driven by the increasing adoption of liquid embolic agents and the growing number of endovascular procedures.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Liquid Embolic Market Key Players And Competitive Insights**

Major players in the Liquid Embolic Market industry are constantly striving to gain a competitive edge by investing in research and development, expanding their product portfolios, and acquiring smaller players. Leading Liquid Embolic Market players are focusing on developing innovative products that cater to the evolving needs of healthcare providers and patients. The increasing prevalence of vascular diseases, technological advancements, and rising healthcare expenditure drive the Liquid Embolic Market development.

The Liquid Embolic Market Competitive Landscape is expected to remain highly competitive, with new entrants and established players vying for market share.Medtronic, a leading company in Liquid Embolic Market, offers a broad range of liquid embolic products for various clinical applications. The company's portfolio includes Onyx, a non-adhesive liquid embolic system that is widely used for embolizing brain aneurysms and arteriovenous malformations. Medtronic also provides technical support and training to healthcare professionals to ensure optimal outcomes.

The company's strong brand recognition, extensive distribution network, and commitment to innovation contribute to its leadership position in the market.Boston Scientific, a prominent competitor in Liquid Embolic Market, offers a comprehensive portfolio of liquid embolic for diverse medical specialties, including interventional radiology, neurology, and oncology. The company's flagship product, Embosphere Microspheres, is a biocompatible and bioresorbable embolic agent used for embolizing hypervascular tumors and controlling bleeding. Boston Scientific is dedicated to advancing liquid embolization techniques through research and development, expanding its global presence, and collaborating with healthcare professionals to improve patient care.

### **Key Companies in the Liquid Embolic Market Include**

## **Liquid Embolic Market Industry Developments**

The Liquid Embolic Market is projected to reach USD 15.7 billion by 2032, exhibiting a CAGR of 7.68% during the forecast period (2024-2032). The increasing prevalence of vascular malformations and the rising demand for minimally invasive procedures are key factors driving market growth. Technological advancements, such as the development of biocompatible and biodegradable embolic agents, are further fueling market expansion. Strategic collaborations and acquisitions among market players are also shaping the competitive landscape.

Recent news developments include the FDA approval of Embozene Microspheres for embolization procedures and the acquisition of Neuravi by Stryker, reflecting the growing focus on innovation and consolidation in the market.

## Liquid Embolic Market Segmentation Insights

### **Liquid Embolic Market Therapeutic Modality Outlook**

### **Liquid Embolic Market Application Outlook**

### **Liquid Embolic Market End User Outlook**

### **Liquid Embolic Market Regional Outlook**

## Market Drivers

### Increasing Prevalence of Vascular Diseases

The rising incidence of vascular diseases, including arteriovenous malformations and aneurysms, is a primary driver for the Liquid Embolic Market. As healthcare systems strive to address these conditions, the demand for effective treatment options has surged. According to recent data, vascular diseases account for a significant percentage of global morbidity and mortality, necessitating innovative solutions.
 
Liquid embolics offer a minimally invasive alternative, which aligns with the current trend towards less invasive surgical techniques. This shift not only enhances patient recovery times but also reduces overall healthcare costs. Consequently, the increasing prevalence of vascular diseases is likely to propel the growth of the Liquid Embolic Market, as healthcare providers seek to adopt advanced technologies that improve patient outcomes.

### Regulatory Approvals and Market Accessibility

The landscape of the Liquid Embolic Market is being shaped by the evolving regulatory environment, which is increasingly favoring the approval of innovative medical devices. Regulatory bodies are streamlining the approval processes for liquid embolic agents, recognizing their potential to improve patient outcomes.
 
This trend is likely to enhance market accessibility, allowing manufacturers to introduce new products more rapidly. As a result, the competition within the Liquid Embolic Market is expected to intensify, leading to a wider variety of options for healthcare providers. This increased accessibility may also encourage further research and development, ultimately benefiting patients through improved treatment options.

### Rising Investment in Healthcare Infrastructure

The ongoing investment in healthcare infrastructure, particularly in developing regions, is poised to impact the Liquid Embolic Market positively. Governments and private entities are increasingly allocating resources to enhance healthcare facilities and expand access to advanced medical technologies.
 
This trend is particularly evident in regions where healthcare systems are evolving to meet the needs of growing populations. As healthcare infrastructure improves, the availability of liquid embolic agents is expected to increase, facilitating their adoption in clinical practice. Moreover, enhanced training programs for healthcare professionals will likely lead to a greater understanding and utilization of liquid embolics, thereby driving market growth.

### Technological Innovations in Liquid Embolic Agents

Technological advancements in the formulation and delivery of liquid embolic agents are transforming the Liquid Embolic Market. Innovations such as improved biocompatibility and enhanced imaging capabilities are making these agents more effective and safer for patients. For instance, the development of new polymers and additives has led to embolics that can be precisely delivered to targeted sites, minimizing collateral damage to surrounding tissues.
 
 Furthermore, the integration of imaging technologies allows for real-time monitoring during procedures, enhancing the overall efficacy of treatments. As these technologies continue to evolve, they are expected to drive market growth by attracting more healthcare professionals to adopt liquid embolic solutions in their practice.

### Growing Preference for Minimally Invasive Techniques

The increasing preference for minimally invasive techniques among both patients and healthcare providers is a significant driver of the Liquid Embolic Market. Patients are increasingly seeking procedures that offer reduced recovery times, less pain, and minimal scarring. Liquid embolics, which can be administered through small incisions or even via catheterization, align perfectly with these patient preferences.
 
Market data indicates that the minimally invasive surgery segment is projected to grow substantially, with liquid embolics playing a crucial role in this expansion. As more practitioners recognize the benefits of these techniques, the demand for liquid embolic agents is likely to rise, further propelling the market forward.

## Future Outlook

The Liquid Embolic Market size is projected to reach USD 6.082 Billion by 2035, growing at a CAGR of 7.7%

**New opportunities:**

- Development of biodegradable liquid embolics for enhanced patient safety. Expansion into emerging markets with tailored product offerings. Partnerships with healthcare providers for integrated embolization solutions.

By 2035, the Liquid Embolic Market is expected to achieve substantial growth, solidifying its position as a key player in the medical device industry.

## Segment Insights

### By Therapeutic Modality: N-Butyl Cyanoacrylate (Largest) vs. Ethylene Vinyl Alcohol Copolymer (Fastest-Growing)

In the Liquid Embolic Market, N-Butyl Cyanoacrylate (NBCA) holds a significant share due to its extensive application in a variety of therapeutic interventions, particularly in vascular occlusion. Its versatility and efficacy in achieving rapid solidification and occlusion have made it a preferred choice among healthcare professionals, leading to a strong market presence. Meanwhile, Ethylene Vinyl Alcohol Copolymer (Onyx) is gaining traction as an innovative solution for more complex cases requiring controlled embolization, marking it as a significant player in the market.

N-Butyl Cyanoacrylate (Dominant) vs. Ethylene Vinyl Alcohol Copolymer (Emerging)

N-Butyl Cyanoacrylate (NBCA) stands out as the dominant player in the market share, renowned for its quick polymerization and efficiency in various embolization procedures. Its application across neurosurgery and vascular treatments underscores its wide acceptance and reliability. In contrast, Ethylene Vinyl Alcohol Copolymer (Onyx) is emerging as a powerful alternative, particularly valued in intricate embolization scenarios. It offers benefits such as controlled delivery and superior visibility under imaging, appealing to specialists seeking more tailored embolic solutions. This positions Onyx for growth as newer techniques and patient needs evolve, making it a notable segment in the market.

### By Application: Arteriovenous Malformations (AVMs) (Largest) vs. Dural Arteriovenous Fistulas (DAVFs) (Fastest-Growing)

The Liquid Embolic Market reveals a diverse application landscape, with Arteriovenous Malformations (AVMs) representing the largest share. Their persistent prevalence in the neurosurgical domain provides a solid foundation for sustained demand, positioning them at the forefront of clinical interventions. In contrast, Dural Arteriovenous Fistulas (DAVFs), while currently a smaller segment, have been rapidly gaining traction, driven by advancements in endovascular techniques and increased clinical awareness among practitioners. Recent trends indicate a surge in both market segments tied to emerging technologies and enhanced procedural outcomes. The robust clinical efficacy associated with liquid embolic agents used for AVMs bolsters their dominance. Meanwhile, the fastest growth of DAVFs is supported by an expanding referral base from general practitioners and heightened urgency to address these conditions effectively, which amplifies their market presence moving forward.

AVMs (Dominant) vs. DAVFs (Emerging)

Arteriovenous Malformations (AVMs) represent the dominant force in the market share, due to their established role in neurosurgical treatments. AVMs are characterized by a tangle of abnormal blood vessels connecting arteries and veins, posing significant health risks; hence, effective treatment is paramount. This segment enjoys robust clinical validation and a history of successful case studies, leading to a strong recommendation among neurosurgeons. In contrast, Dural Arteriovenous Fistulas (DAVFs), while emerging in the market landscape, are receiving recognition for their complex vascular structures and potential serious complications. Their growth is spurred by advancements in minimally invasive techniques, making the treatment more accessible and effective, which is gradually increasing their share in healthcare resources.

### By End User: Hospitals (Largest) vs. Neurointerventional Centers (Fastest-Growing)

In the Liquid Embolic Market, hospitals dominate the end-user segment, accounting for a significant share due to their extensive infrastructure and established operational protocols. Conversely, neurointerventional centers are emerging rapidly, reflecting a growing preference for specialized care in neurovascular procedures. These centers are increasingly recognized for their efficacy in handling complex cases, positioning them as a vital component in the market landscape. The growth trends in this segment are largely driven by advancements in liquid embolic technologies and an increasing number of minimally invasive procedures. Hospitals are leveraging these innovations to enhance patient outcomes, while neurointerventional centers are benefiting from the rising demand for specialized treatment. This trend is expected to continue, contributing to a more competitive and varied market with rising investments in both hospital and specialized neurointerventional settings.

Hospitals (Dominant) vs. ASCs (Emerging)

Hospitals are the dominant end-user segment in the market share, offering an advantage due to their comprehensive facilities, specialist staff, and ability to manage complex patient cases. Their established relationships with suppliers and extensive resources allow them to adopt and implement new technologies effectively. In contrast, Ambulatory Surgical Centers (ASCs) are emerging as a significant player, driven by the demand for outpatient procedures. ASCs provide cost-effective and efficient alternatives for liquid embolic treatments, allowing for faster patient turnover and reduced hospital stays. This shift towards ASCs is illustrative of a broader trend in healthcare towards outpatient services, which is expected to augment their market share and create a competitive environment for hospitals.

## Regional Market Share Analysis

North America leads in the Liquid Embolic Market Size, accounting for over 44.88% of the global revenue in 2024.The growth of the North American market is attributed to the increasing prevalence of vascular diseases, the rising demand for minimally invasive procedures, and the growing adoption of advanced embolic agents.

The European market is also growing steadily, driven by the increasing awareness of liquid embolic agents and the growing number of endovascular procedures.The APAC market is expected to witness significant growth in the coming years, owing to the rising incidence of vascular diseases and the growing healthcare expenditure in the region. The South American and MEA markets are also expected to grow at a healthy pace, driven by the increasing adoption of liquid embolic agents and the growing number of endovascular procedures.

## Competitive Benchmarking

Major players in the Liquid Embolic Market industry are constantly striving to gain a competitive edge by investing in research and development, expanding their product portfolios, and acquiring smaller players. Leading Liquid Embolic Market players are focusing on developing innovative products that cater to the evolving needs of healthcare providers and patients.
 
The increasing prevalence of vascular diseases, technological advancements, and rising healthcare expenditure drive the Liquid Embolic Market development. The Liquid Embolic Market Competitive Landscape is expected to remain highly competitive, with new entrants and established players vying for market share.Medtronic, a leading company in Liquid Embolic Market, offers a broad range of liquid embolic products for various clinical applications. The company's portfolio includes Onyx, a non-adhesive liquid embolic system that is widely used for embolizing brain aneurysms and arteriovenous malformations.
 
Medtronic also provides technical support and training to healthcare professionals to ensure optimal outcomes. The company's strong brand recognition, extensive distribution network, and commitment to innovation contribute to its leadership position in the market.Boston Scientific, a prominent competitor in Liquid Embolic Market, offers a comprehensive portfolio of liquid embolic for diverse medical specialties, including interventional radiology, neurology, and oncology.
 
The company's flagship product, Embosphere Microspheres, is a biocompatible and bioresorbable embolic agent used for embolizing hypervascular tumors and controlling bleeding. Boston Scientific is dedicated to advancing liquid embolization techniques through research and development, expanding its global presence, and collaborating with healthcare professionals to improve patient care.

## Recent News & Developments

The Liquid Embolic Market is projected to reach USD 15.7 billion by 2032, exhibiting a CAGR of 7.68% during the forecast period (2024-2032). The increasing prevalence of vascular malformations and the rising demand for minimally invasive procedures are key factors driving market growth. Technological advancements, such as the development of biocompatible and biodegradable embolic agents, are further fueling market expansion. Strategic collaborations and acquisitions among market players are also shaping the competitive landscape.

Recent news developments include the FDA approval of Embozene Microspheres for embolization procedures and the acquisition of Neuravi by Stryker, reflecting the growing focus on innovation and consolidation in the market.

## Liquid Embolic Market Segmentation Insights

### **Liquid Embolic Market Therapeutic Modality Outlook**

- N-Butyl Cyanoacrylate (NBCA)
- Ethylene Vinyl Alcohol Copolymer (Onyx)
- Polyvinyl Alcohol (PVA)

### **Liquid Embolic Market Application Outlook**

- Arteriovenous Malformations (AVMs)
- Dural Arteriovenous Fistulas (DAVFs)
- Carotid Cavernous Fistulas (CCFs)

### **Liquid Embolic Market End User Outlook**

- Hospitals
- Ambulatory Surgical Centers (ASCs)
- Neurointerventional Centers

### **Liquid Embolic Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa

## Report Scope

| MARKET SIZE 2024 | 8.69(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 9.357(USD Billion) |
| MARKET SIZE 2035 | 19.61(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.68% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Medtronic (US), Johnson & Johnson (US), Stryker (US), Terumo Corporation (JP), Penumbra, Inc. (US), B. Braun Melsungen AG (DE), Boston Scientific Corporation (US), Cook Medical (US), Asahi Intecc Co., Ltd. (JP) |
| Segments Covered | Therapeutic Modality, Application, End User, Regional |
| Key Market Opportunities | Advancements in minimally invasive procedures drive demand for innovative solutions in the Liquid Embolic Market. |
| Key Market Dynamics | Rising demand for minimally invasive procedures drives innovation and competition in the liquid embolic market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Liquid Embolic Market as of 2024?**
A: The Liquid Embolic Market was valued at 8.69 USD Billion in 2024.

**Q: What is the projected market size for the Liquid Embolic Market in 2035?**
A: The market is projected to reach 19.61 USD Billion by 2035.

**Q: What is the expected CAGR for the Liquid Embolic Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Liquid Embolic Market during 2025 - 2035 is 7.68%.

**Q: Which therapeutic modalities are leading in the Liquid Embolic Market?**
A: N-Butyl Cyanoacrylate (NBCA) and Ethylene Vinyl Alcohol Copolymer (Onyx) are leading modalities, with valuations of 5.93 and 7.93 USD Billion respectively by 2035.

**Q: What applications are driving growth in the Liquid Embolic Market?**
A: Arteriovenous Malformations (AVMs) and Carotid Cavernous Fistulas (CCFs) are key applications, projected to reach 5.93 and 8.73 USD Billion respectively by 2035.

**Q: Who are the key players in the Liquid Embolic Market?**
A: Key players include Medtronic, Johnson & Johnson, Stryker, and Terumo Corporation, among others.

**Q: What end-user segments are contributing to the Liquid Embolic Market?**
A: Hospitals and Ambulatory Surgical Centers (ASCs) are significant end-users, with projected valuations of 8.0 and 5.8 USD Billion respectively by 2035.

**Q: How does the market for Polyvinyl Alcohol (PVA) compare to other modalities?**
A: Polyvinyl Alcohol (PVA) is projected to reach 5.75 USD Billion by 2035, indicating robust growth compared to other modalities.

**Q: What is the growth outlook for Dural Arteriovenous Fistulas (DAVFs) in the Liquid Embolic Market?**
A: The market for Dural Arteriovenous Fistulas (DAVFs) is expected to grow to 4.95 USD Billion by 2035.

**Q: How are advancements in technology influencing the Liquid Embolic Market?**
A: Advancements in technology are likely to enhance the efficacy and safety of liquid embolics, potentially driving market growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/liquid-embolic-market-41151*